港股異動丨微創機器人-B(2252.HK)續升超7%再度破頂 市值逼近700億港元
格隆匯11月16日丨微創機器人-B(2252.HK)再度拉昇漲超7%,高見73.45港元刷新歷史高價,較招股價43.2港元累計漲幅達70%,總市值逼近700億港元大關。公司由微創醫療分拆而來,也是港股第一家手術機器人公司。目前公司市值逼近母公司微創醫療。公司是全球行業中唯一一家擁有覆蓋五大主要手術專科(即腔鏡、骨科、泛血管、經自然腔道及經皮穿刺手術)產品組合的公司。 據悉,公司三維電子內窺鏡蜻蜓眼於2021年6月獲批,腔鏡手術機器人圖邁於2021年5月完成臨牀試驗並提交註冊申請,預計2022年有望獲批,骨科機器人鴻鵠也已完成註冊臨牀試驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.